Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox Regulatory Dossier accepted for review in Canada

Jun 15, 2017Mark EdwardsNews

15 June 2017

ASX ANNOUNCEMENT

Penthrox Regulatory Dossier accepted for review in Canada

Medical Developments International Limited (ASX: MVP) is delighted to announce that the regulatory dossier for Penthrox? submitted in Canada has now been accepted for review by the Canadian regulatory body, Health Canada.

Accepting the MVP dossier for review, triggers a milestone payment of CAD$0.25 million from MVP?s partner, Purdue Pharma (Canada).

MVP Chief Executive Officer, Mr. John Sharman said: ?This is another positive step towards globalizing Penthrox.?

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

  • MVP Board Re-organisation

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.